Literature DB >> 22971779

Misdiagnosis of late-onset Lyme arthritis by inappropriate use of Borrelia burgdorferi immunoblot testing with synovial fluid.

Sam S Barclay1, Michael T Melia, Paul G Auwaerter.   

Abstract

The primary objective of this study was to determine whether patients with putative late-onset Lyme arthritis based upon synovial fluid Borrelia burgdorferi IgM and IgG immunoblot testing offered by commercial laboratories satisfied conventional criteria for the diagnosis of Lyme arthritis. Secondary objectives included assessing the prior duration and responsiveness of associated antibiotic therapy. We conducted a retrospective analysis of 11 patients referred to an academic medical center infectious disease clinic during the years 2007 to 2009 with a diagnosis of Lyme disease based upon previously obtained synovial fluid B. burgdorferi immunoblot testing. Ten of the 11 (91%) patients with a diagnosis of late-onset Lyme arthritis based upon interpretation of synovial fluid B. burgdorferi immunoblot testing were seronegative and did not satisfy published criteria for the diagnosis of late-onset Lyme arthritis. None of the 10 patients had a clinical response to previously received antibiotics despite an average course of 72 days. Diagnosis of Lyme arthritis should not be based on synovial fluid B. burgdorferi immunoblot testing. This unvalidated test does not appear useful for the diagnosis of Lyme disease, and this study reinforces the longstanding recommendation to use B. burgdorferi immunoblot testing only on serum samples and not other body fluids. Erroneous interpretations of "positive" synovial fluid immunoblots may lead to inappropriate antibiotic courses and delays in diagnosis of other joint diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971779      PMCID: PMC3491552          DOI: 10.1128/CVI.00383-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  14 in total

1.  High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice.

Authors:  V Seriburi; N Ndukwe; Z Chang; M E Cox; G P Wormser
Journal:  Clin Microbiol Infect       Date:  2012-02-28       Impact factor: 8.067

Review 2.  A critical appraisal of "chronic Lyme disease".

Authors:  Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

Review 3.  Diagnosis and treatment of Lyme arthritis.

Authors:  A C Steere
Journal:  Med Clin North Am       Date:  1997-01       Impact factor: 5.456

4.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

5.  Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.

Authors:  J E Craft; D K Fischer; G T Shimamoto; A C Steere
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

Review 6.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

7.  Prospective study of serologic tests for lyme disease.

Authors:  Allen C Steere; Gail McHugh; Nitin Damle; Vijay K Sikand
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

8.  Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'.

Authors:  R B Nadelman; Z Arlin; G P Wormser
Journal:  South Med J       Date:  1991-10       Impact factor: 0.954

9.  Lyme arthritis: oligoclonal anti-Borrelia burgdorferi IgG antibodies occur in joint fluid and serum.

Authors:  M Cruz; K Hansen; J Ernerudh; A C Steere; H Link
Journal:  Scand J Immunol       Date:  1991-01       Impact factor: 3.487

Review 10.  Potential for tick-borne bartonelloses.

Authors:  Emmanouil Angelakis; Sarah A Billeter; Edward B Breitschwerdt; Bruno B Chomel; Didier Raoult
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

View more
  5 in total

Review 1.  Laboratory diagnosis of Lyme disease: advances and challenges.

Authors:  Adriana R Marques
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 2.  Diagnosis and treatment of Lyme arthritis.

Authors:  Sheila L Arvikar; Allen C Steere
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 3.  Lyme Arthritis.

Authors:  Sheila L Arvikar; Allen C Steere
Journal:  Infect Dis Clin North Am       Date:  2022-09       Impact factor: 5.905

Review 4.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

Review 5.  Postoperative Lyme Arthritis in the Orthopaedic Patient.

Authors:  Matthew C Hess; Zachary Devilbiss; Garry Wai Keung Ho; Raymond Thal
Journal:  Sports Health       Date:  2019-05-28       Impact factor: 3.843

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.